抗精神病药对青少年脂肪与胰岛素敏感性的代谢影响:随机临床试验
该随机临床试验纳入144例6至18岁未用过抗精神病药、有破坏性行为障碍的青少年,随机接受阿立哌唑、奥氮平或利培酮治疗12周。结果显示奥氮平组体脂百分比增加最显著,全样本胰岛素敏感性显著下降,行为均有改善。
要点
- 奥氮平治疗12周体脂百分比增加4.12%,显著高于利培酮(1.18%)和阿立哌唑(1.66%)。
- 全样本胰岛素敏感性在12周内显著下降(时间效应P<.001)。
- 三种药物均改善行为,但需权衡代谢风险。
核心结论
- 青少年接受12周抗精神病药治疗出现脂肪增加和胰岛素敏感性下降,奥氮平脂肪增加最明显。
- 这些变化可能归因于治疗,并与早发心血管代谢疾病风险相关。
研究设计与样本
- 随机临床试验,1:1:1分配至阿立哌唑(n=49)、奥氮平(n=46)或利培酮(n=49),治疗12周。
- 纳入6至18岁未用过抗精神病药、诊断至少一种精神障碍且有临床显著攻击行为的青少年,来自圣路易斯地区。
- 主要结局为双能X线吸收法测定的全身脂肪百分比和高胰岛素正葡萄糖钳夹测定的肌肉胰岛素敏感性。
主要发现
- 从基线至第12周,全身脂肪百分比增加:利培酮1.18%、奥氮平4.12%、阿立哌唑1.66%,奥氮平显著高于另两组(时间×治疗交互P<.001)。
- 胰岛素刺激的葡萄糖消失率变化:利培酮增加2.30%,奥氮平下降29.34%,阿立哌唑下降30.26%,组间无显著差异(时间×治疗交互P<.07)。
- 全样本胰岛素敏感性主要指标在12周内显著下降(时间效应F=17.38;P<.001)。
- MRI测定的腹部皮下脂肪增加,奥氮平显著高于利培酮或阿立哌唑(时间×治疗交互P=.003)。
- 所有治疗均观察到行为改善。
临床怎么用
- 对青少年使用抗精神病药时应监测体脂和胰岛素敏感性,尤其奥氮平代谢风险更高。
- 需结合行为改善与代谢风险进行个体化风险-获益评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antipsychotic medications are commonly used to treat nonpsychotic disruptive behavioral disorders in youths. OBJECTIVE: To characterize the metabolic effects of first exposure to antipsychotics in youths using criterion standard assessments of body composition and insulin sensitivity. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial recruited antipsychotic-naive youths aged 6 to 18 years in the St Louis, Missouri, metropolitan area who were diagnosed with 1 or more psychiatric disorders and clinically significant aggression and in whom antipsychotic treatment was considered. Participants were enrolled from June 12, 2006, through November 10, 2010. Enrolled participants were randomized (1:1:1) to 1 of 3 antipsychotics commonly used in children with disruptive behavioral disorders and evaluated for 12 weeks. Data were analyzed from January 17, 2011, through August 9, 2017. INTERVENTIONS: Twelve weeks of treatment with oral aripiprazole (n = 49), olanzapine (n = 46), or risperidone (n = 49). MAIN OUTCOMES AND MEASURES: Primary outcomes included percentage total body fat measured by dual-energy x-ray absorptiometry (DXA) and insulin sensitivity in muscle measured via hyperinsulinemic clamps with stable isotopically labeled tracers. Secondary outcomes included abdominal adiposity measured by magnetic resonance imaging (MRI) and adipose and hepatic tissue insulin sensitivity measured via clamps with tracers. RESULTS: The intention-to-treat sample included 144 participants (98 males [68.1%]; mean [SD] age, 11.3 [2.8] years); 74 (51.4%) were African American, and 43 (29.9%) were overweight or obese at baseline. For the primary outcomes, from baseline to week 12, DXA percentage total body fat increased by 1.18% for risperidone, 4.12% for olanzapine, and 1.66% for aripiprazole and was significantly greater for olanzapine than risperidone or aripiprazole (time by treatment interaction P < .001). From baseline to week 12, insulin-stimulated change in glucose rate of disappearance increased by 2.30% for risperidone and decreased by 29.34% for olanzapine and 30.26% for aripiprazole, with no significant difference across medications (time by treatment interaction, P < .07). This primary measure of insulin sensitivity decreased significantly during 12 weeks in the pooled study sample (effect of time, F = 17.38; P < .001). For the secondary outcomes from baseline to week 12, MRI measured abdominal fat increased, with subcutaneous fat increase significantly greater for olanzapine than risperdone or aripiprazole (time by treatment, P = .003). Behavioral improvements occurred with all treatments. CONCLUSIONS AND RELEVANCE: Adverse changes in adiposity and insulin sensitivity were observed during 12 weeks of antipsychotic treatment in youths, with the greatest fat increases on olanzapine. Such changes, likely attributable to treatment, may be associated with risk for premature cardiometabolic morbidity and mortality. The results inform risk-benefit considerations for antipsychotic use in youths. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00205699.
引用
- Nicol GE, Yingling MD, Flavin KS, et al. Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29898210. doi:10.1001/jamapsychiatry.2018.1088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。